PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial ...
- Company hosting a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT to discuss results PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback